Targeting tumors with an off-the-shelf, cell-based immune primer
Immunicum’s lead development candidate ilixadencel uses dendritic cells sourced from healthy human donors that are specifically activated to produce significant amounts of vigorous immune stimulatory factors. By administration through intratumoral injection, these cells induce a local inflammatory reaction, leading to destruction of tumor cells, and recruitment and activation of the patient’s own dendritic cells into the tumor environment. The recruited dendritic cells will encounter and engulf dying tumor cells, including the full array of tumor specific proteins, called neoantigens, that will act as an antigen source to activate and educate the tumor specific T cells, specifically cytotoxic CD8+ T cells, resulting in a highly personalized and potent anti-tumor response.
In addition to the ongoing Phase II MERECA study in metastatic renal cell carcinoma (mRCC), Ilixadencel has been evaluated in clinical trials for a range of solid tumors including hepatocellular carcinoma and gastrointestinal stromal tumor.